

LPL - PRODUCTION TEST COLLECTION CENTRE SECTOR - 18, BLOCK-E ROHINI DELHI 110085

Name : DUMMY Collected : 29/5/2021 1:37:00AM

Lab No. : DUMMYF009 Age: 25 Years Gender: Male Received : 29/5/2021 4:27:12PM Reported : 1/6/2021 2:54:57PM

A/c Status : P Ref By : DR. DUMMY DUMMY Report Status : Final

Test Name	Results	Units	Bio. Ref. Interval
CA 72.4 (TAG-72) GASTRIC CANCER MARKER,	23.00	U/mL	<6.90
SERUM			
(ECLIA)			

Note

- 1. This test is not recommended to screen Gastric cancer in the general population.
- 2. Sensitivity of monitoring Gastric carcinoma improves by combining CA 72.4 with CEA and CA 19.9 assays.
- 3. False negative/positive results are observed in patients receiving mouse monoclonal antibodies for diagnosis or therapy
- 4. This assay, regardless of level, should not be interpreted as absolute evidence for the presence or absence of malignant disease. The assay value should be used in conjunction with findings from clinical evaluation and other diagnostic procedures.
- 5. Patients receiving Biotin therapy in high doses should not be tested for at least 8 hours after the last dose.

Clinical Use

- An aid in the management of Gastric cancer patients
- Monitor the course of disease and predict recurrence in patients with Gastric carcinoma
- Useful in detecting residual tumor

DISEASE	PERCENTAGE POSITIVITY OF CA 72.4	
Gastro-intestinal carcinoma	40	
Lung cancer	36	
Ovarian cancer	24	
Benign gastro-intestinal diseases	6.7	
Healthy individuals	3.5	

Increased Levels

- Gastric carcinoma
- Ovarian carcinoma
- Benign diseases Pancreatitis, Cirrhosis, Pulmonary disease, Rheumatic conditions, Ovarian cysts,
 Benign breast disease, Benign gastro-intestinal disorders



Page 1 of 2



LPL - PRODUCTION TEST COLLECTION CENTRE **SECTOR - 18, BLOCK-E ROHINI DELHI 110085**

Name **DUMMY** Collected

Units

: 29/5/2021 1:37:00AM

Lab No.

DUMMYF009 Age: 25 Years Received

: 29/5/2021 4:27:12PM

Bio. Ref. Interval

Test Name

Male

: 1/6/2021 2:54:57PM Reported

Ref By: DR. DUMMY DUMMY A/c Status

Report Status : Final

Dr Himangshu Mazumdar MD. Biochemistry

Senior Consultant - Clinical Chemistry & Biochemical Genetics NRL - Dr Lal PathLabs Ltd

Dr Kamal Modi MD. Biochemistry

Consultant Biochemist NRL - Dr Lal PathLabs Ltd MD. Biochemistry

National Head - Clinical Chemistry &

Biochemical Genetics NRL - Dr Lal PathLabs Ltd

----End of report ---

Gender:

Results

IMPORTANT INSTRUCTIONS

*Test results released pertain to the specimen submitted.*All test results are dependent on the quality of the sample received by the Laboratory *Laboratory investigations are only a tool to facilitate in arriving at a diagnosis <mark>and</mark> should be clinically correlated by the Referring Physician .*Sample repeats are accepted on request of Referring Physician within 7 days post reporting.*Report delivery may be delayed due to unforeseen circumstances. Inconvenience is regretted.*Certain tests may re<mark>qu</mark>ire <mark>furt</mark>her testing at additional cost for derivation of exact value. Kindly submit request within 72 hours post reporting.*Test results may show inter<mark>la</mark>boratory variations.*The Courts/Forum at Delhi shall have exclusive jurisdiction in all disputes/claims concerning the test(s) & or results of test(s).*Test results are not valid for medico legal purposes. *Contact customer care Tel No. +91-11-39885050 for all queries related to test results.

(#) Sample drawn from outside source.

